NSCLC

ASCO Updates Systemic Therapy Guideline for NSCLC With Driver Alterations
ASCO Updates Systemic Therapy Guideline for NSCLC With Driver Alterations
03/09/2021
The American Society of Clinical Oncology released an update to its guideline on systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations.
The American Society of Clinical Oncology released an update to its guideline on systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations.
The American Society of Clinical...
03/09/2021
Journal of Clinical Pathways
Research in Review
Equivalent Outcomes With Two NSCLC Treatment Options
08/04/2016
JCP Editors
Erlotinib may be an effective therapeutic option for patients with pretreated advanced non-small cell lung cancer (NSCLC) and no known molecular alterations, according to a study published in the journal Lung...
Erlotinib may be an effective therapeutic option for patients with pretreated advanced non-small cell lung cancer (NSCLC) and no known molecular alterations, according to a study published in the journal Lung...
...
08/04/2016
Journal of Clinical Pathways
Research in Review
Cost-Effectiveness of Two NSCLC Treatments Compared
07/15/2016
JCP Editors
Compared with docetaxel, nivolumab is not a cost-effective treatment option for nonsquamous non-small cell lung cancer unless its price is reduced or it is used after programmed death ligand 1 (PD-L1) testing,...
Compared with docetaxel, nivolumab is not a cost-effective treatment option for nonsquamous non-small cell lung cancer unless its price is reduced or it is used after programmed death ligand 1 (PD-L1) testing,...
...
07/15/2016
Journal of Clinical Pathways
Quality Measures for NSCLC Significantly Improve Survival
05/20/2016
JCP Editors
Including certain quality measures as a part of care for patients with non-small cell lung cancer (NSCLC) who undergo surgery can significantly improve survival, according to results presented at the American...
Including certain quality measures as a part of care for patients with non-small cell lung cancer (NSCLC) who undergo surgery can significantly improve survival, according to results presented at the American...
...
05/20/2016
Journal of Clinical Pathways
Research in Review
Blood Biopsy Test Ready for Use in Patients With NSCLC
04/14/2016
JCP Editors
A newly developed “liquid biopsy” assay that detects free-floating DNA from cells in blood plasma may be an effective tool for detecting mutations in patients with non-small cell lung cancer (NSCLC), according to the...
A newly developed “liquid biopsy” assay that detects free-floating DNA from cells in blood plasma may be an effective tool for detecting mutations in patients with non-small cell lung cancer (NSCLC), according to the...
A...
04/14/2016
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use